No Data
No Data
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
Express News | HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Express News | Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate